Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;15(1):25-28.
doi: 10.2185/jrm.2019-004. Epub 2020 Jan 23.

Initial treatment outcome and feasibility of low-dose cabazitaxel against docetaxel- and castration-resistant prostate cancer in a Japanese hospital

Ryosuke Chaya  1   2 , Takehiko Okamura  1 , Takahiro Yanase  1 , Takashi Nagai  1 , Yoshinobu Moritoki  1 , Daichi Kobayashi  1 , Hidetoshi Akita  1 , Takahiro Yasui  2
Affiliations

Initial treatment outcome and feasibility of low-dose cabazitaxel against docetaxel- and castration-resistant prostate cancer in a Japanese hospital

Ryosuke Chaya et al. J Rural Med. 2020 Jan.

Abstract

Introduction: Cabazitaxel (CBZ) is used worldwide for castration-resistant prostate cancer after docetaxel treatment. In July 2014 the drug was approved in Japan with the same induction dose used for Caucasian patients. In this study, we examined and compared the results of an initial low-dose CBZ treatment in patients admitted to our hospital. Patients and Methods: Between July 2014 and August 2018, sixteen mCRPC patients were enrolled and underwent a low-dose CBZ treatment at our hospital. We compared the results with those of a Japanese metastatic docetaxel- and castration-resistant prostate cancer Phase I study. Results: The median patient age was 77 years (range, 53-84 years). Of the 16 patients, eight (50%) had a lymph node metastasis and 11 (68.8%) had a distant metastasis, 10 of whom had only a bone metastasis. The median dose of CBZ was 30 mg (range, 20-32 mg) and the median number of CBZ cycles was 2.5 (range, 1-18). The PSA level of 9 (56.3%) patients decreased after CBZ treatment, including 4 (25%) who showed a decrease to <50%. The median time interval in which the PSA level decreased was 2 months (range, 1-18 months). The observed adverse events (AE) were neutropenia (31.3%), febrile neutropenia (6.3%), fatigue (43.8%), nausea (18.8%), diarrhea (12.5%), decreased appetite (25%), dysgeusia (6.3%), white blood cell count decrease (43.8%), platelet count decrease (12.3%), and anemia (75%). However, no patient listed an AE as the reason for discontinuing the treatment. Conclusions: Even at a low dose, CBZ could improve the PSA value in patients with CRPC previously treated with docetaxel. Dose reduction and prophylactic administration of sustained G-CSF were also safe treatment options. Further studies involving an introduction period including a modulation of duration and dose are necessary, especially in Japanese patients.

Keywords: cabazitaxcel; castration resistant prostate cancer; prostate cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Waterfall plot showing maximum percentage change in prostate-specific antigen (PSA) level from baseline.
Figure 2
Figure 2
Kaplan-Meier curve showing overall survival (OS) after the start of androgen-deprivation therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Jemal A, Bray F, Center MM. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90. doi: 10.3322/caac.20107 - DOI - PubMed
    1. World Health Organization International Agency for Research on Cancer. Global Cancer Observatory. https://gco.iarc.fr. (Accessed May 14, 2019).
    1. Tannock IF, de Wit R, Berry WR. TAX 327 InvestigatorsDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–1512. doi: 10.1056/NEJMoa040720 - DOI - PubMed
    1. de Bono JS, Logothetis CJ, Molina A. COU-AA-301 InvestigatorsAbiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995–2005. doi: 10.1056/NEJMoa1014618 - DOI - PMC - PubMed
    1. Parker C, Nilsson S, Heinrich D. ALSYMPCA InvestigatorsAlpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213–223. doi: 10.1056/NEJMoa1213755 - DOI - PubMed